Biotechs Befriend Non-Dilutive Funds

"Few have raised “non-dilutive” financing better than Achaogen Inc., an antibiotics developer. Because antibiotic resistance is a public-health problem, and because Achaogen’s drugs may also work against bio-terrorism threats like anthrax, the South San Francisco company has been able to supplement its $41 million in venture financing..."

Brian Gormley
The Wall Street Journal: Venture Capital Dispatch

Read article @ blogs.wsj.com